Phase 3 · NEJM 2026

Survodutide SYNCHRONIZE-1: what the phase 3 data actually shows

📄 7 PubMed citations

The once-weekly glucagon/GLP-1 dual agonist reduced body weight by up to 13.0% at 76 weeks — real and clinically meaningful, but below the phase 2 headline and below tirzepatide. Here's the honest read of the numbers.

🔬 Most coverage repeats the phase 2 hype. We put SYNCHRONIZE-1’s conservative treatment-regimen numbers side by side with the phase 2 trial and with tirzepatide so the real delta — and survodutide’s genuine liver advantage — is visible.
13%
Mean weight loss at 76 weeks (6.0 mg, treatment-regimen estimand)
725
Adults with obesity randomized (3.6 / 6.0 mg / placebo)
84%
Had ≥30% liver-fat reduction in the SYNCHRONIZE-MASLD trial

How It Works

🧬
Dual receptor agonism

Survodutide activates BOTH the GLP-1 receptor (appetite, satiety, glucose control) and the glucagon receptor. Layering glucagon agonism on top of GLP-1 is the design bet behind its weight-loss and liver-fat effects.

🔥
Glucagon = energy expenditure & liver

Unlike pure GLP-1 drugs, the glucagon arm is intended to raise energy expenditure and drive hepatic fat oxidation — the mechanistic basis for survodutide’s strong MASH / liver-fat signal.

💉
Once-weekly, slowly titrated

Subcutaneous once-weekly, escalated up to 3.6 mg or 6.0 mg. Slow titration is required because gastrointestinal side effects are the main tolerability limit.

📉
Why the headline reads "13%"

SYNCHRONIZE-1’s primary number uses the conservative treatment-regimen estimand, which counts early discontinuations and rescue-medication use — so it reads lower than phase 2’s on-treatment figures.

What the Data Shows

Survodutide 6.0 mg
SYNCHRONIZE-1, wk76 (treatment-regimen)
-13.0%
Survodutide 3.6 mg
SYNCHRONIZE-1, wk76 (treatment-regimen)
-12.2%
Survodutide 4.8 mg
Phase 2, wk46 (planned treatment)
-14.9%
Placebo
SYNCHRONIZE-1, wk76
-5.4%
Tirzepatide 15 mg
SURMOUNT-1, wk72 (context, indirect)
-20.9%

Key Takeaways

✅ What We Know
  • SYNCHRONIZE-1 (n=725) met both primary endpoints: mean weight change at week 76 was -12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% for placebo (treatment-regimen estimand).
  • 72.6% (3.6 mg) and 71.9% (6.0 mg) of participants lost at least 5% of body weight vs 46.3% on placebo (P<0.001 for all comparisons).
  • The 3.6 mg and 6.0 mg doses produced almost identical weight loss — going higher added little, largely because gastrointestinal tolerability caps the achievable dose.
  • In the separate SYNCHRONIZE-MASLD phase 3 trial, 84.2% of survodutide-treated patients had a ≥30% reduction in liver fat vs 24.3% on placebo — the glucagon arm gives a real liver advantage over pure GLP-1 drugs.
  • Phase 2 MASH data showed histologic MASH improvement without worsening fibrosis in up to 62% of patients (4.8 mg) vs 14% on placebo.
  • Gastrointestinal side effects dominate the safety profile: reported by 80.9% (3.6 mg) and 89.7% (6.0 mg) of participants, typically mild-to-moderate; no deaths were reported.
⚠️ What We Don't Know
  • Whether survodutide is more or less effective than tirzepatide — cross-trial numbers (~13% vs ~21%) are indirect and no head-to-head trial has been run.
  • How it performs in people with type 2 diabetes — SYNCHRONIZE-1 excluded diabetes; that population is studied separately in SYNCHRONIZE-2.
  • Long-term (multi-year) weight maintenance and hard cardiovascular outcomes — the SYNCHRONIZE cardiovascular outcomes trial is still ongoing.
  • Which estimand best predicts real-world results — the on-treatment figures are higher than the ~13% headline, and the gap depends on how well a person tolerates the GI side effects.
  • When or whether it will be approved or available — survodutide is investigational, not FDA/EMA-approved, and is not sold as a research chemical or by consumer vendors.

Frequently Asked Questions

What is survodutide and how does it work?

Survodutide (BI 456906) is an investigational once-weekly injectable that activates both the GLP-1 receptor and the glucagon receptor. GLP-1 activity suppresses appetite and improves glucose handling, while glucagon activity is intended to raise energy expenditure and reduce liver fat — a dual mechanism that pure GLP-1 drugs like semaglutide do not have.

What did the SYNCHRONIZE-1 phase 3 trial show?

In 725 adults with obesity and without diabetes, once-weekly survodutide reduced body weight by a mean of 12.2% (3.6 mg) to 13.0% (6.0 mg) at week 76 versus 5.4% on placebo (treatment-regimen estimand). About 72% of participants on each dose lost at least 5% of body weight versus 46% on placebo.

How does survodutide compare to tirzepatide (Mounjaro/Zepbound)?

No head-to-head trial exists. Indirectly, survodutide’s ~13% treatment-regimen weight loss at 76 weeks reads below tirzepatide’s ~20.9% at 15 mg in SURMOUNT-1, but the trials used different designs, doses and estimands, so the comparison is approximate. Survodutide’s distinguishing feature is its liver-fat benefit.

Why is survodutide considered promising for fatty liver (MASH/MASLD)?

Its glucagon arm drives hepatic fat oxidation. In the SYNCHRONIZE-MASLD phase 3 trial, 84.2% of treated patients had a ≥30% reduction in liver fat versus 24.3% on placebo, and phase 2 data showed histologic MASH improvement in up to 62% of patients — a signal stronger than typical GLP-1 monotherapy.

Is survodutide FDA-approved or available to buy?

No. Survodutide is investigational, developed by Boehringer Ingelheim and Zealand Pharma, and is in phase 3 trials. It is not approved by the FDA or EMA and is not legitimately available as a research chemical or from consumer vendors.

Peer-Reviewed References

Source 1
Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1)
N Engl J Med · 2026
PMID: 42253238
Source 2
Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD, a phase 3 trial
Nat Med · 2026
PMID: 42252333
Source 3
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
N Engl J Med · 2024
PMID: 38847460
Source 4
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a dose-finding phase 2 trial
Lancet Diabetes Endocrinol · 2024
PMID: 38330987
Source 5
Survodutide for obesity: rationale and design of SYNCHRONIZE-1 and -2 phase 3 trials
Obesity (Silver Spring) · 2025
PMID: 39495965
Source 6
Efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis
J Hepatol · 2024
PMID: 38857788
Source 7
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
N Engl J Med · 2022
PMID: 35658024
⚠️ Disclaimer

Educational purposes only. Not medical advice.

Survodutide is investigational and not approved by the FDA or EMA. Cross-trial comparisons are indirect. Consult a licensed clinician before making any treatment decisions.